Nicolas Venteclef
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nicolas Venteclef has a total of 485 co-authors. Here are the top co-authors by number of shared publications:
Karine Clément
1] Sorbonne Universités, Université Pierre et Marie-Curie; INSERM UMR_S 1166-ICAN, Nutriomics, Paris, France. [2] Institute of Cardiometabolism and Nutrition, Paris, France. [3] Heart and Metabolism Division, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
13 shared publications- Fawaz Alzaid
Department of Bioenergetics & Neurometabolism, Dasman Diabetes Institute, Dasman 15462, Kuwait
10 shared publications - Eckardt Treuter
Department of Medicine Huddinge, Unit for Gastroenterology and Nutrition, Karolinska Institutet, Huddinge, Sweden
9 shared publications Eckardt Treuter
Department of Biosciences and Nutrition Karolinska Institute Huddinge Sweden
7 shared publicationsAmine Toubal
INEM
6 shared publications- Jean-François Gautier
INEM Institut Necker-Enfants Malades, INSERM U1151, CNRS UMR 8253, Université Paris Cité, Paris, France; Centre Universitaire du Diabète et de ses Complications, AP-HP, Hôpital Lariboisière, INSERM UMR-S1151, CNRS UMR-S8253, Immediab Lab, Institut Necker-Enfants Malades, Université Paris Cité, Paris, France
6 shared publications
Latest Publications
- Open Access
Rev-erbα inhibits vascular calcification by repressing osteogenic reprogramming in atherosclerosis
Background: Atherosclerotic plaque rupture is the leading cause of fatal atherothrombotic events, including myocardial infarction. Intimal microcalcification is a major determinant of plaque instability, but its pathogenic mechanisms remain poorly understood. The nuclear receptor Rev-erbα regulates lipoprotein metabolism and inflammation. We hypothesized that it modulates atherogenesis by also controlling arterial calcification. Methods: To identify regulators of vascular calcification, transcriptomic analysis of CD14 + CD16 - monocytes from diabetic patients with different calcium scores (ANGIOSAFE cohort) was combined with targeted analysis in calcified and non-calcified atherosclerotic plaques from diabetic and non-diabetic patients (AtheroPortal cohort) and in calcified and non-calcified areas of human endarterectomies isolated by laser capture microdissection (OPAL Cohort). Functional relevance was evaluated in 18-month-old Ldlr -/- mouse and in primary aortic vascular smooth muscle cells after targeting Rev-erbα. Results: In ANGIOSAFE (n=668), REV-ERBα expression was lower in classical CD14⁺CD16⁻ monocytes from diabetic patients with low coronary artery calcium scores. In the AtheroPortal cohort (n=968), REV-ERBα expression was reduced in highly calcified plaques from diabetic patients, and laser capture microdissection confirmed lower expression in calcified compared to non-calcified areas of human endarterectomies. Rev-erbα-deficient Ldlr -/- mice displayed accelerated atherogenesis and calcification, with SMCs reprogrammed toward an osteochondroblastic phenotype. In vitro , Rev-erbα preserved SMC identity by repressing IL-1β-driven transdifferentiation, notably via Spp1, Osterix and Sox9, and repressed the hyaluronidase Cemip, whose activity degrades hyaluronic acid and promotes intimal calcification. Conclusions: Rev-erbα restrains SMC-driven vascular calcification by suppressing osteogenic reprogramming and may represent a therapeutic target to reduce calcification and cardiovascular risk in high-risk patients.
Open AccessRev-erbα inhibits vascular calcification by repressing osteogenic reprogramming in atherosclerosis
Background: Atherosclerotic plaque rupture is the leading cause of fatal atherothrombotic events, including myocardial infarction. Intimal microcalcification is a major determinant of plaque instability, but its pathogenic mechanisms remain poorly understood. The nuclear receptor Rev-erbα regulates lipoprotein metabolism and inflammation. We hypothesized that it modulates atherogenesis by also controlling arterial calcification. Methods: To identify regulators of vascular calcification, transcriptomic analysis of CD14 + CD16 - monocytes from diabetic patients with different calcium scores (ANGIOSAFE cohort) was combined with targeted analysis in calcified and non-calcified atherosclerotic plaques from diabetic and non-diabetic patients (AtheroPortal cohort) and in calcified and non-calcified areas of human endarterectomies isolated by laser capture microdissection (OPAL Cohort). Functional relevance was evaluated in 18-month-old Ldlr -/- mouse and in primary aortic vascular smooth muscle cells after targeting Rev-erbα. Results: In ANGIOSAFE (n=668), REV-ERBα expression was lower in classical CD14⁺CD16⁻ monocytes from diabetic patients with low coronary artery calcium scores. In the AtheroPortal cohort (n=968), REV-ERBα expression was reduced in highly calcified plaques from diabetic patients, and laser capture microdissection confirmed lower expression in calcified compared to non-calcified areas of human endarterectomies. Rev-erbα-deficient Ldlr -/- mice displayed accelerated atherogenesis and calcification, with SMCs reprogrammed toward an osteochondroblastic phenotype. In vitro , Rev-erbα preserved SMC identity by repressing IL-1β-driven transdifferentiation, notably via Spp1, Osterix and Sox9, and repressed the hyaluronidase Cemip, whose activity degrades hyaluronic acid and promotes intimal calcification. Conclusions: Rev-erbα restrains SMC-driven vascular calcification by suppressing osteogenic reprogramming and may represent a therapeutic target to reduce calcification and cardiovascular risk in high-risk patients.
- 25 August 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 2018-2035.e6
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
- 25 August 2026
- Published by Elsevier in Cell Metabolism
- Vol. 38 (10) , 2018-2035.e6
Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes
- Open Access
- 13 May 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5 (6)
Oncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disorders
PIK3CA-related overgrowth spectrum (PROS) comprises a group of rare genetic disorders caused by de novo, mosaic, postzygotic gain-of-function mutations in the PIK3CA gene. These mutations arise during embryogenesis, affect multiple organ systems, and result in heterogeneous clinical phenotypes. We previously showed that primary cells derived from a PROS mouse model exhibit a metabolic shift toward aerobic glycolysis (a Warburg-like effect), accompanied by altered secretion of metabolites. Here, we observed that this metabolic reprogramming was associated with the up-regulation of key transcription factors, including cellular myelocytomatosis and hypoxia-inducible factor 1 alpha. PIK3CA hyperactivation induces a distinct microenvironment marked by metabolic dysregulation, extracellular matrix remodeling, increased cellular proliferation, elevated phosphorylated form of the histone variant H2AX levels, and enhanced macrophage infiltration, hallmarks commonly associated with increased lactate production. To further examine immune infiltration dynamics, we used a mouse model expressing a constitutively active PIK3CA mutation selectively in adipose tissue (AdipoCreER), a tissue frequently affected in PROS. Single-cell transcriptomics and flow cytometry profiling revealed that macrophages adopt an immunomodulatory phenotype, with increased infiltration of TREM2+ and Lyve1hiMHCIIlo macrophages, along with myeloid-derived suppressor cells, and a concurrent reduction in T-cell populations. These immune alterations parallel those observed in tumor microenvironments and may contribute to tissue overgrowth and impaired immune surveillance. Multiplex immunofluorescence analysis of tissue samples from individuals with PROS confirmed these findings, underscoring the translational relevance of the mouse model. Together, our results demonstrate that PIK3CA mutations in PROS profoundly remodel the tissue microenvironment and reprogram macrophage function in a manner reminiscent of tumor biology.
- 13 May 2026
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 5 (6)
Open AccessOncogenic PIK3CA mutations shape an immunoregulatory microenvironment in mosaic overgrowth disorders
PIK3CA-related overgrowth spectrum (PROS) comprises a group of rare genetic disorders caused by de novo, mosaic, postzygotic gain-of-function mutations in the PIK3CA gene. These mutations arise during embryogenesis, affect multiple organ systems, and result in heterogeneous clinical phenotypes. We previously showed that primary cells derived from a PROS mouse model exhibit a metabolic shift toward aerobic glycolysis (a Warburg-like effect), accompanied by altered secretion of metabolites. Here, we observed that this metabolic reprogramming was associated with the up-regulation of key transcription factors, including cellular myelocytomatosis and hypoxia-inducible factor 1 alpha. PIK3CA hyperactivation induces a distinct microenvironment marked by metabolic dysregulation, extracellular matrix remodeling, increased cellular proliferation, elevated phosphorylated form of the histone variant H2AX levels, and enhanced macrophage infiltration, hallmarks commonly associated with increased lactate production. To further examine immune infiltration dynamics, we used a mouse model expressing a constitutively active PIK3CA mutation selectively in adipose tissue (AdipoCreER), a tissue frequently affected in PROS. Single-cell transcriptomics and flow cytometry profiling revealed that macrophages adopt an immunomodulatory phenotype, with increased infiltration of TREM2+ and Lyve1hiMHCIIlo macrophages, along with myeloid-derived suppressor cells, and a concurrent reduction in T-cell populations. These immune alterations parallel those observed in tumor microenvironments and may contribute to tissue overgrowth and impaired immune surveillance. Multiplex immunofluorescence analysis of tissue samples from individuals with PROS confirmed these findings, underscoring the translational relevance of the mouse model. Together, our results demonstrate that PIK3CA mutations in PROS profoundly remodel the tissue microenvironment and reprogram macrophage function in a manner reminiscent of tumor biology.
- Open Access
- 12 December 2025
- Published by Springer Nature in Research Square
The Histone Demethylase KDM6B Governs the LYVE1+ Perivascular Macrophage Phenotype to Control Adipose Tissue Expandability through BMP2 signaling
The capacity of white adipose tissue (WAT) to expand in response to energy surplus is a key factor in determining metabolic health. In obesity, this expansion becomes dysregulated and contributes to metabolic dysfunction, insulin resistance and type 2 diabetes. Phenotypically diverse subtypes of adipose tissue macrophages (ATMs) control WAT plasticity, yet the underlying regulatory mechanisms and factors have remained enigmatic. Here, we identify the lysine demethylase KDM6B (aka JMJD3) as an essential epigenetic and transcriptional regulator that specifies ATM phenotypes during WAT expansion. We first show that KDM6B expression in human ATMs correlates with insulin sensitivity, glycemic control and levels of WAT inflammation. Single-cell RNA sequencing of both human and mouse ATMs revealed that KDM6B is predominantly expressed in LYVE1⁺CD206⁺ perivascular macrophages (PVMs), where it is essential for their maintenance and endocytic function. Myeloid-specific depletion of Kdm6b in mice triggers a phenotypic shift of PVMs, resulting in accumulation of CD9⁺CD63⁺ lipid-associated macrophages (LAMs) and impaired WAT expansion marked by adipocyte hypertrophy, vascular rarefaction and increased inflammation. Consequently, Kdm6b-deficient mice develop pronounced insulin resistance and a pro-diabetic state when exposed to a high-fat diet. We uncover that KDM6B governs the transcriptional program of PVMs, including the regulation of adipogenesis, through BMP2 signaling. Mechanistically, KDM6B directly regulates Bmp2 expression in PVMs through demethylation of H3K27me3 at the Bmp2 promoter. Myeloid-specific depletion of Bmp2 partially mimics the WAT phenotype seen in Kdm6b-deficient mice, characterized by adipocyte hypertrophy. Overall, our study identifies the KDM6B–BMP2 axis as an ATM-intrinsic epigenetic and transcriptional regulator that couples immune cell phenotypes to WAT expandability and metabolic health.
- 12 December 2025
- Published by Springer Nature in Research Square
Open AccessThe Histone Demethylase KDM6B Governs the LYVE1+ Perivascular Macrophage Phenotype to Control Adipose Tissue Expandability through BMP2 signaling
The capacity of white adipose tissue (WAT) to expand in response to energy surplus is a key factor in determining metabolic health. In obesity, this expansion becomes dysregulated and contributes to metabolic dysfunction, insulin resistance and type 2 diabetes. Phenotypically diverse subtypes of adipose tissue macrophages (ATMs) control WAT plasticity, yet the underlying regulatory mechanisms and factors have remained enigmatic. Here, we identify the lysine demethylase KDM6B (aka JMJD3) as an essential epigenetic and transcriptional regulator that specifies ATM phenotypes during WAT expansion. We first show that KDM6B expression in human ATMs correlates with insulin sensitivity, glycemic control and levels of WAT inflammation. Single-cell RNA sequencing of both human and mouse ATMs revealed that KDM6B is predominantly expressed in LYVE1⁺CD206⁺ perivascular macrophages (PVMs), where it is essential for their maintenance and endocytic function. Myeloid-specific depletion of Kdm6b in mice triggers a phenotypic shift of PVMs, resulting in accumulation of CD9⁺CD63⁺ lipid-associated macrophages (LAMs) and impaired WAT expansion marked by adipocyte hypertrophy, vascular rarefaction and increased inflammation. Consequently, Kdm6b-deficient mice develop pronounced insulin resistance and a pro-diabetic state when exposed to a high-fat diet. We uncover that KDM6B governs the transcriptional program of PVMs, including the regulation of adipogenesis, through BMP2 signaling. Mechanistically, KDM6B directly regulates Bmp2 expression in PVMs through demethylation of H3K27me3 at the Bmp2 promoter. Myeloid-specific depletion of Bmp2 partially mimics the WAT phenotype seen in Kdm6b-deficient mice, characterized by adipocyte hypertrophy. Overall, our study identifies the KDM6B–BMP2 axis as an ATM-intrinsic epigenetic and transcriptional regulator that couples immune cell phenotypes to WAT expandability and metabolic health.
- Open Access
- 8 October 2025
- Published by Springer Nature in Research Square
Immune Cell-Based Clustering Reveals Clinically Distinct Endotypes in Type 2 Diabetes
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications fail to capture its complexity or enable precision care. Here, we introduce a clinically scalable, immune-based endotyping strategy using routine blood immune cell counts - neutrophils, lymphocytes, and monocytes - from over 1,500 individuals with newly diagnosed T2D across three independent longitudinal European cohorts. Unsupervised clustering identified four consistent and clinically meaningful immune endotypes: Severe Inflammatory Diabetes (SIND), Mild Inflammatory Diabetes (MIND), Lymphocyte-Rich Diabetes (LYRD), and Lymphocyte-Deficient Diabetes (LYDD), that named immunotypes. These endotypes were associated with divergent long-term outcomes, with SIND and LYDD showing increased cardiovascular, renal, and mortality risks, and MIND and LYRD linked to more favorable trajectories. Multi-omic profiling revealed endotype-specific inflammatory signatures, including selective expansion of CCR2hi and CD39hi classical monocytes in the SIND endotype. Integration with single-cell RNA-seq uncovered distinct monocyte subsets in SIND, enriched for chemotaxis and myeloid activation transcriptional programs, alongside skewed adaptive immunity. Strikingly, this pro-inflammatory immune profile was attenuated by IL-1β antagonism and bariatric surgery-induced diabetes remission, underscoring its therapeutic relevance. These findings position immune-based endotyping as a robust and accessible tool to stratify risk, uncover disease mechanisms, and guide personalized intervention strategies in T2D.
- 8 October 2025
- Published by Springer Nature in Research Square
Open AccessImmune Cell-Based Clustering Reveals Clinically Distinct Endotypes in Type 2 Diabetes
Type 2 diabetes (T2D) is a heterogeneous disease, yet current classifications fail to capture its complexity or enable precision care. Here, we introduce a clinically scalable, immune-based endotyping strategy using routine blood immune cell counts - neutrophils, lymphocytes, and monocytes - from over 1,500 individuals with newly diagnosed T2D across three independent longitudinal European cohorts. Unsupervised clustering identified four consistent and clinically meaningful immune endotypes: Severe Inflammatory Diabetes (SIND), Mild Inflammatory Diabetes (MIND), Lymphocyte-Rich Diabetes (LYRD), and Lymphocyte-Deficient Diabetes (LYDD), that named immunotypes. These endotypes were associated with divergent long-term outcomes, with SIND and LYDD showing increased cardiovascular, renal, and mortality risks, and MIND and LYRD linked to more favorable trajectories. Multi-omic profiling revealed endotype-specific inflammatory signatures, including selective expansion of CCR2hi and CD39hi classical monocytes in the SIND endotype. Integration with single-cell RNA-seq uncovered distinct monocyte subsets in SIND, enriched for chemotaxis and myeloid activation transcriptional programs, alongside skewed adaptive immunity. Strikingly, this pro-inflammatory immune profile was attenuated by IL-1β antagonism and bariatric surgery-induced diabetes remission, underscoring its therapeutic relevance. These findings position immune-based endotyping as a robust and accessible tool to stratify risk, uncover disease mechanisms, and guide personalized intervention strategies in T2D.
- Open Access
BMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity
Contemporary lifestyle modifications such as changes in nutritional and sleep/wake rhythms increase the risk of metabolic and inflammatory complications linked to obesity, including type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH). BMAL2 (Brain and Muscle ARNT Like Protein 2) is a transcription factor belonging to the circadian clock transcriptional feedback loop which synchronizes internal biological rhythms to environment. In humans, reduced expression in white adipose tissue (WAT) and specific polymorphisms of BMAL2 are associated with obesity and T2D. In this study we report that Bmal2 invalidation in mice leads to increased body weight gain during diet-induced obesity. Loss of BMAL2 triggers the inflammatory response by increasing Tnfα expression and modifying adipocyte progenitor fate. This results in reduced lipid storage capacity within the WAT and increased ectopic storage in the liver. These functional and structural alterations culminate in the onset of hepatic steatosis and insulin resistance in liver and WAT. Overall, our investigations underscore the role of BMAL2 in the development and function of adipocytes, as well as in their inflammatory potential within the WAT. Our findings contribute to the understanding of the role of circadian clock genes in obesity and interconnected metabolic complications. Highlights: The transcription factor BMAL2 is involved in metabolic complications of obesity in a mouse model of diet-induced obesity Invalidation of Bmal2 worsens insulin resistance and hepatic steatosis induced by high fat diet Invalidation of Bmal2 impairs visceral adipose tissue adaptation capacity in promoting inflammation and adipose progenitor decline Graphical
Open AccessBMAL2 controls adipose tissue inflammation and metabolic adaptation during obesity
Contemporary lifestyle modifications such as changes in nutritional and sleep/wake rhythms increase the risk of metabolic and inflammatory complications linked to obesity, including type 2 diabetes (T2D) and metabolic dysfunction-associated steatohepatitis (MASH). BMAL2 (Brain and Muscle ARNT Like Protein 2) is a transcription factor belonging to the circadian clock transcriptional feedback loop which synchronizes internal biological rhythms to environment. In humans, reduced expression in white adipose tissue (WAT) and specific polymorphisms of BMAL2 are associated with obesity and T2D. In this study we report that Bmal2 invalidation in mice leads to increased body weight gain during diet-induced obesity. Loss of BMAL2 triggers the inflammatory response by increasing Tnfα expression and modifying adipocyte progenitor fate. This results in reduced lipid storage capacity within the WAT and increased ectopic storage in the liver. These functional and structural alterations culminate in the onset of hepatic steatosis and insulin resistance in liver and WAT. Overall, our investigations underscore the role of BMAL2 in the development and function of adipocytes, as well as in their inflammatory potential within the WAT. Our findings contribute to the understanding of the role of circadian clock genes in obesity and interconnected metabolic complications. Highlights: The transcription factor BMAL2 is involved in metabolic complications of obesity in a mouse model of diet-induced obesity Invalidation of Bmal2 worsens insulin resistance and hepatic steatosis induced by high fat diet Invalidation of Bmal2 impairs visceral adipose tissue adaptation capacity in promoting inflammation and adipose progenitor decline Graphical
- 4 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (10) , e3334-e3342
Body-weight Cycling and Risk of Diabetic Kidney Disease in People With Type 1 Diabetes in the DCCT/EDIC Population
Context: Intraindividual body-weight variability or cycling is associated with increased risk of chronic kidney disease (CKD) in the general population. Objective: We conducted a retrospective analysis of data from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) studies to assess association between body-weight cycling and the risk of renal events in type 1 diabetes. Methods: Four indices of intraindividual body-weight variability were calculated for 1432 participants of DCCT/EDIC taking into account body-weight measurements during the DCCT follow-up (6 ± 2 years). Variability independent of the mean (VIM) was the main index. Six criteria of progression to CKD were studied during DCCT/EDIC follow-up (21 ± 4 years). Hazard ratio (HR) with 95% confidence interval (CI) were computed in Cox analyses for 1 SD of the indices expressed as Z-score. Results: A high VIM was significantly associated with the incidence of a 40% decline in eGFR from baseline values (HR, 1.25; 95% CI, 1.09-1.41; P = .001), doubling of baseline serum creatinine (HR, 1.34; 95% CI, 1.13-1.57; P = .001), CKD stage 3 (HR, 1.36; 95% CI, 1.12-1.63; P = .002), and with a decline in eGFR > 3 mL/min/m2 per year (all analyses adjusted for CKD risk factors at baseline and follow-up, and use of nephroprotective drugs). VIM was also associated with the incidence of moderately and severely increased albuminuria, but associations did not remain significant following adjustment for follow-up covariates. Similar results were observed for the other indices of body-weight cycling. Conclusion: Body-weight cycling is significantly associated with an increased risk of kidney events in people with type 1 diabetes, regardless of body mass index and traditional risk factors.
- 4 February 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (10) , e3334-e3342
Body-weight Cycling and Risk of Diabetic Kidney Disease in People With Type 1 Diabetes in the DCCT/EDIC Population
Context: Intraindividual body-weight variability or cycling is associated with increased risk of chronic kidney disease (CKD) in the general population. Objective: We conducted a retrospective analysis of data from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) studies to assess association between body-weight cycling and the risk of renal events in type 1 diabetes. Methods: Four indices of intraindividual body-weight variability were calculated for 1432 participants of DCCT/EDIC taking into account body-weight measurements during the DCCT follow-up (6 ± 2 years). Variability independent of the mean (VIM) was the main index. Six criteria of progression to CKD were studied during DCCT/EDIC follow-up (21 ± 4 years). Hazard ratio (HR) with 95% confidence interval (CI) were computed in Cox analyses for 1 SD of the indices expressed as Z-score. Results: A high VIM was significantly associated with the incidence of a 40% decline in eGFR from baseline values (HR, 1.25; 95% CI, 1.09-1.41; P = .001), doubling of baseline serum creatinine (HR, 1.34; 95% CI, 1.13-1.57; P = .001), CKD stage 3 (HR, 1.36; 95% CI, 1.12-1.63; P = .002), and with a decline in eGFR > 3 mL/min/m2 per year (all analyses adjusted for CKD risk factors at baseline and follow-up, and use of nephroprotective drugs). VIM was also associated with the incidence of moderately and severely increased albuminuria, but associations did not remain significant following adjustment for follow-up covariates. Similar results were observed for the other indices of body-weight cycling. Conclusion: Body-weight cycling is significantly associated with an increased risk of kidney events in people with type 1 diabetes, regardless of body mass index and traditional risk factors.
- 13 June 2024
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 85 (3) , 210
Immune cells in adipose tissue: The ying and yang of metabolism?
- 13 June 2024
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 85 (3) , 210
Immune cells in adipose tissue: The ying and yang of metabolism?
- 19 January 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (2) , 189-202
Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes
BACKGROUND: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are inflammatory effector cells involved in both type 2 diabetes (T2D) and atherogenesis. METHODS: We investigated the relationship between circulating monocytes and cardiovascular risk progression in people with T2D, using phenotypic, transcriptomic, and metabolomic analyses. cardiovascular risk progression was estimated with coronary artery calcium score in a cohort of 672 people with T2D. RESULTS: Coronary artery calcium score was positively correlated with blood monocyte count and frequency of the classical monocyte subtype. Unsupervised k-means clustering based on monocyte subtype profiles revealed 3 main endotypes of people with T2D at varying risk of cardiovascular events. These observations were confirmed in a validation cohort of 279 T2D participants. The predictive association between monocyte count and major adverse cardiovascular events was validated through an independent prospective cohort of 757 patients with T2D. Integration of monocyte transcriptome analyses and plasma metabolomes showed a disruption of mitochondrial pathways (tricarboxylic acid cycle, oxidative phosphorylation pathway) that underlined a proatherogenic phenotype. CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04353869
- 19 January 2024
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 134 (2) , 189-202
Blood Monocyte Phenotype Is A Marker of Cardiovascular Risk in Type 2 Diabetes
BACKGROUND: Diabetes is a major risk factor for atherosclerotic cardiovascular diseases with a 2-fold higher risk of cardiovascular events in people with diabetes compared with those without. Circulating monocytes are inflammatory effector cells involved in both type 2 diabetes (T2D) and atherogenesis. METHODS: We investigated the relationship between circulating monocytes and cardiovascular risk progression in people with T2D, using phenotypic, transcriptomic, and metabolomic analyses. cardiovascular risk progression was estimated with coronary artery calcium score in a cohort of 672 people with T2D. RESULTS: Coronary artery calcium score was positively correlated with blood monocyte count and frequency of the classical monocyte subtype. Unsupervised k-means clustering based on monocyte subtype profiles revealed 3 main endotypes of people with T2D at varying risk of cardiovascular events. These observations were confirmed in a validation cohort of 279 T2D participants. The predictive association between monocyte count and major adverse cardiovascular events was validated through an independent prospective cohort of 757 patients with T2D. Integration of monocyte transcriptome analyses and plasma metabolomes showed a disruption of mitochondrial pathways (tricarboxylic acid cycle, oxidative phosphorylation pathway) that underlined a proatherogenic phenotype. CONCLUSIONS: In this study, we provide evidence that frequency and monocyte phenotypic profile are closely linked to cardiovascular risk in patients with T2D. The assessment of monocyte frequency and count is a valuable predictive marker for risk of cardiovascular events in patients with T2D. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04353869